Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | FFAR2 | O15552 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rentiapril SCHEMBL30422754 | 1.00 | ACE (1.00) | ACELMNAFFAR2ALDH1A1POLB | |
| Rentiapril SCHEMBL323403 | 1.00 | ACE (1.00) | ACELMNAFFAR2ALDH1A1POLB | |
| Rentiapril SCHEMBL11065900 | 1.00 | ACE (1.00) | ACELMNAFFAR2ALDH1A1POLB | |
| SCHEMBL683207 | 0.93 | ACE (0.87) | ACELMNAFFAR2ALDH1A1POLB | |
| SCHEMBL11063036 | 0.90 | ACE (0.82) | ACELMNAFFAR2ALDH1A1POLB | |
| SCHEMBL11004289 | 0.89 | ACE (0.80) | ACELMNAFFAR2ALDH1A1POLB | |
| SCHEMBL8398559 | 0.89 | ACE (0.80) | ACELMNAFFAR2ALDH1A1POLB | |
| SCHEMBL10944184 | 0.89 | ACE (0.80) | ACELMNAFFAR2ALDH1A1POLB | |
| SCHEMBL10942930 | 0.88 | ACE (0.78) | ACELMNAFFAR2ALDH1A1POLB | |
| SCHEMBL11202128 | 0.88 | ACE (0.78) | ACELMNAFFAR2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1802 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739293-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | AZURA OPHTHALMICS LTD (IL) | 2026-05-13 | — | — | EP | claimed |
| EP-4739291-A2 | ADMINISTRATION OF KERATOLYTICS TO OCULAR AND PERIOCULAR SURFACES | AZURA OPHTHALMICS LTD (IL) | 2026-05-13 | — | — | EP | claimed |
| WO-2026041906-A1 | SEMI-SOLID PHARMACEUTICAL COMPOSITION MICRO-DISPENSER | Azura Ophthalmics Ltd. (IL) | 2026-02-26 | — | — | WO | claimed |
| WO-2025012701-A2 | ADMINISTRATION OF KERATOLYTICS TO OCULAR AND PERIOCULAR SURFACES | Azura Ophthalmics Ltd. (IL) | 2025-01-16 | — | — | WO | claimed |
| WO-2025012700-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | Azura Ophthalmics Ltd. (IL) | 2025-01-16 | — | — | WO | claimed |
| WO-2024100454-A2 | COMPOSITION AND METHODS FOR IMPROVING SIGNS AND SYMPTOMS OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2024-05-16 | — | — | WO | claimed |
| US-20230372370-A1 | USE OF CANNABINOIDS IN THE TREATMENT OF COVID-19 | Orcosa Inc. (US) | 2023-11-23 | — | — | US | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| US-20200179440-A1 | THIOL AND DISULFIDE-CONTAINING AGENTS FOR INCREASING MEIBOMIAN GLAND LIPID SECRETION | M.G. THERAPEUTICS LTD. (IL) | 2020-06-11 | — | — | US | claimed |
| EP-0209897-A2 | Peptide enzyme inhibitors | MERCK & CO. INC. (US) | 1987-01-28 | — | — | EP | claimed |
| EP-0163237-A2 | Di- and tri-peptidal renin inhibitors | MERCK & CO. INC. (US) | 1985-12-04 | — | — | EP | claimed |
| EP-0157409-A2 | Renin inhibitors containing 2-substituted statine | MERCK & CO. INC. (US) | 1985-10-09 | — | — | EP | claimed |
| EP-0156318-A2 | C-terminal amide cyclic renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0156322-A2 | Renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0072868-B1 | CYCLODEXTRIN CLATHRATE COMPOUNDS OF SULFUR-CONTAINING COMPOUNDS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1985-07-24 | — | — | EP | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
| US-4482709-A | Inclusion compounds of cyclodextrin with sulfur-containing compounds | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1984-11-13 | — | — | US | claimed |
| US-4424228-A | Antihypertensive agent comprising a thiazolidine carboxylic acid and probenecid | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1984-01-03 | — | — | US | claimed |
| EP-0072868-A1 | CYCLODEXTRIN CLATHRATE COMPOUNDS OF SULFUR-CONTAINING COMPOUNDS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1983-03-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179440-A1 | THIOL AND DISULFIDE-CONTAINING AGENTS FOR INCREASING MEIBOMIAN GLAND LIPID SECRETION | TXN, MGST3, MGST1 | ACE 3798/4885LMNA 4767/4885FFAR2 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.